Antiemetics: 5‑Hydroxyltryptamine‑3 Receptor Antagonists and Neurokinin‑1 Receptor Antagonists

Introduction / Overview

Emesis constitutes a distressing symptom that interferes markedly with patient comfort, nutritional intake, and treatment adherence. In oncologic, surgical, and peri‑operative settings, the prevention of nausea and vomiting has become a cornerstone of patient‑centered care. Among the pharmacologic armamentarium, selective antagonists of the 5‑hydroxyltryptamine‑3 (5‑HT₃) and neurokinin‑1 (NK1) receptors have revolutionised antiemetic therapy. Their efficacy, safety profiles, and evidence‑based dosing regimens make them indispensable for modern clinical practice. This chapter is intended to provide medical and pharmacy students with a comprehensive understanding of these agents, encompassing pharmacology, clinical application, and practical considerations.

• Learning objectives:
  1. Describe the pharmacologic classification and chemical characteristics of 5‑HT₃ and NK1 antagonists.
  2. Explain the receptor‑level mechanisms that mediate antiemetic activity.
  3. Summarise pharmacokinetic properties relevant to dosing and drug interactions.
  4. Identify approved therapeutic indications and common off‑label uses.
  5. Recognise adverse effect profiles, drug interactions, and special population considerations.

Classification

Drug Classes and Categories

• 5‑Hydroxyltryptamine‑3 Receptor Antagonists – these agents competitively inhibit the 5‑HT₃ receptor, which is widely expressed in the central nervous system and gastrointestinal tract. Representative drugs include ondansetron, granisetron, dolasetron, palonosetron, and tropisetron. They are available in oral, intravenous, and subcutaneous formulations.
• Neurokinin‑1 Receptor Antagonists – these molecules block the NK1 receptor, thereby inhibiting the emetogenic actions of substance P. The most prominent drug in this class is aprepitant, with fosaprepitant serving as its intravenous prodrug. Other agents, such as netupitant (combined with palonosetron in NEPA) and rolapitant, have also entered clinical practice.

Chemical Classification

• 5‑HT₃ antagonists share a tricyclic core structure that allows for specific binding to the ligand‑binding pocket of the receptor. Variations in side‑chain substitutions confer differences in potency, half‑life, and metabolic pathways.
• NK1 antagonists possess a more diverse chemical scaffold; for example, aprepitant is a tricyclic compound containing a quinazoline ring, while netupitant incorporates a substituted indole moiety. These structural differences influence receptor affinity and pharmacokinetic behavior.

Mechanism of Action

Pharmacodynamics of 5‑HT₃ Antagonists

5‑HT₃ receptors are ligand‑gated ion channels located predominantly on vagal afferents, the area postrema, and enteric neurons. Activation of these receptors by serotonin released during chemotherapy or postoperative stress initiates the emetic reflex. Competitive antagonism at the receptor site prevents ion flux, thereby blunting the afferent signal that propagates to the vomiting center. The high affinity of palonosetron for the 5‑HT₃ receptor, coupled with its long half‑life, may also induce receptor internalization, contributing to prolonged antiemetic effects.

Pharmacodynamics of NK1 Antagonists

Substance P, the principal ligand for the NK1 receptor, is released in the central nervous system and the gastrointestinal tract during emetogenic stimuli. NK1 antagonists block the binding of substance P to its receptor, thereby interrupting the signal transduction pathway that culminates in nausea and vomiting. Aprepitant, for instance, exhibits high affinity and selectivity for the NK1, and its sustained occupancy is associated with effective suppression of delayed emesis. Combination therapy with 5‑HT₃ antagonists often yields synergistic benefits, as the two pathways act at different points in the emetic circuitry.

Molecular and Cellular Mechanisms

• In the peripheral pathway, serotonin released from enterochromaffin cells during chemotherapy activates 5‑HT₃ receptors on vagal afferents, which then transmit signals to the nucleus tractus solitarius and the vomiting center.
• Substance P, released centrally, binds NK1 receptors on the dorsal vagal complex, amplifying the emetic signal.
• By blocking these receptors, antiemetics interrupt both peripheral and central components, resulting in comprehensive suppression of the emetic reflex.

Pharmacokinetics

Absorption

Orally administered 5‑HT₃ antagonists typically achieve peak plasma concentrations within 1–2 h post‑dose. Palonosetron, due to its higher lipophilicity, shows a slightly delayed absorption profile but maintains sustained plasma levels. Intravenous formulations bypass first‑pass metabolism, achieving immediate therapeutic concentrations. NK1 antagonists demonstrate variable oral bioavailability; aprepitant’s oral bioavailability is approximately 60 %, whereas its intravenous prodrug fosaprepitant converts to aprepitant via phosphatase activity, ensuring rapid systemic exposure.

Distribution

Both drug classes exhibit extensive plasma protein binding, exceeding 90 % for most 5‑HT₃ antagonists and around 70–80 % for aprepitant. High lipophilicity facilitates penetration of the blood‑brain barrier, enabling central antiemetic action. Volume of distribution values range from 0.5 L/kg (ondansetron) to 3.0 L/kg (palonosetron), reflecting differences in tissue affinity.

Metabolism

Ondansetron, dolasetron, and granisetron undergo hepatic metabolism primarily via cytochrome P450 3A4 (CYP3A4). Palonosetron is metabolized by CYP3A4 and CYP1A2, though its longer half‑life is partly due to a slower metabolic rate. Aprepitant is a potent inhibitor of CYP3A4 and, to a lesser extent, CYP2D6, leading to significant drug interactions. Fosaprepitant is dephosphorylated in the bloodstream, producing aprepitant without further metabolism.

Excretion

Renal elimination accounts for a modest proportion of total clearance. Ondansetron is excreted unchanged in urine (approximately 30 %) and via feces; palonosetron is largely excreted unchanged in feces. Aprepitant undergoes hepatic metabolism; its metabolites are eliminated in bile and urine. Renal impairment may necessitate dose adjustments for agents with substantial renal excretion, although most 5‑HT₃ antagonists remain safe in mild to moderate kidney disease.

Half‑Life and Dosing Considerations

• Ondansetron: 4 h (oral); 4–6 h (IV). Standard dosing: 8–16 mg IV or 32 mg orally 30 min before chemotherapy.
• Granisetron: 1.5 h (oral); 1.5–3 h (IV). Standard dosing: 1 mg IV or 4 mg orally 30 min before chemotherapy.
• Dolasetron: 6 h (oral); 6–9 h (IV). Standard dosing: 4 mg IV 30 min before chemotherapy.
• Palonosetron: 8 h (oral); 8–13 h (IV). Standard dosing: 0.25 mg IV or 0.50 mg orally 30 min before chemotherapy.
• Aprepitant: 9–12 h (oral). Standard dosing: 125 mg on day 1, 80 mg on days 2–3 for chemotherapy‑induced nausea and vomiting.

Theorized Therapeutic Uses / Clinical Applications

Approved Indications

• Acute and Delayed Chemotherapy‑Induced Nausea and Vomiting (CINV) – 5‑HT₃ antagonists constitute first‑line therapy for highly emetogenic chemotherapy, while NK1 antagonists are added for moderate to highly emetogenic regimens.
• Post‑Operative Nausea and Vomiting (PONV) – palonosetron and ondansetron are routinely employed to mitigate PONV in high‑risk surgeries.
• Radiation‑Induced Nausea – 5‑HT₃ antagonists reduce nausea associated with abdominal and pelvic radiotherapy.
• Gastro‑Intestinal Disorders – ondansetron is licensed for non‑intractable nausea and vomiting in adults and children; palonosetron is approved for chemotherapy‑induced nausea and vomiting in pediatric populations.

Off‑Label Uses

• Management of nausea in migraine therapy, particularly when combined with triptans.
• Prevention of nausea associated with spinal anesthesia and epidural analgesia.
• Adjunctive therapy in psychiatric conditions characterized by nausea, such as major depressive disorder and schizophrenia.
• Use in chemotherapy regimens lacking formal approval, such as in combination with novel targeted agents.

Adverse Effects

Common Side Effects

• Headache, constipation, dizziness, and fatigue are frequently reported with 5‑HT₃ antagonists.
• Palonosetron may cause mild sedation and visual disturbances in some patients.
• Aprepitant is associated with fatigue, dizziness, and mild nausea, often self‑limited.

Serious or Rare Adverse Reactions

• QTc prolongation: ondansetron and granisetron may cause dose‑dependent cardiac conduction abnormalities, warranting ECG monitoring in high‑risk patients.
• Allergic reactions: rare anaphylactoid responses have been reported, particularly with intravenous formulations.
• Severe hepatotoxicity: uncommon but documented with palonosetron, especially in patients with pre‑existing liver disease.
• Drug‑induced myoclonus or seizures: exceedingly rare, observed in high‑dose or overdose scenarios.

Black Box Warnings

• Ondansetron carries a black box warning for QTc prolongation in patients with congenital long QT syndrome or those receiving other QT‑prolonging drugs.
• Palonosetron and other 5‑HT₃ antagonists are cautioned in patients with a history of cardiac arrhythmia or electrolyte disturbances.
• Aprepitant is warned against in patients with severe hepatic impairment, given the risk of elevated plasma concentrations.

Drug Interactions

Major Drug‑Drug Interactions

• 5‑HT₃ antagonists inhibit CYP3A4 to varying degrees; co‑administration with potent CYP3A4 substrates (e.g., statins, benzodiazepines) may increase plasma levels of those agents.
• Aprepitant is a strong inhibitor of CYP3A4 and a moderate inhibitor of CYP2D6; concomitant use with drugs metabolised by these enzymes (e.g., warfarin, beta‑blockers, fentanyl) can lead to elevated drug levels and toxicity.
• Fosaprepitant may interact with antiepileptics such as phenytoin, resulting in altered seizure control.
• Serotonin syndrome risk: combining 5‑HT₃ antagonists with serotonergic agents (e.g., selective serotonin reuptake inhibitors, tramadol) may precipitate serotonin syndrome, though the risk remains low.

Contraindications

• Known hypersensitivity to the drug or any excipient.
• Severe cardiac conduction abnormalities (e.g., QTc > 500 ms) for 5‑HT₃ antagonists.
• Severe hepatic dysfunction for NK1 antagonists.
• Pregnancy category X for ondansetron (in the U.S.) due to potential teratogenicity.

Special Considerations

Use in Pregnancy and Lactation

• Animal studies have indicated potential teratogenic effects; thus, 5‑HT₃ antagonists should generally be avoided during pregnancy unless no alternatives exist. Aprepitant has limited human data, but its classification suggests caution.
• Limited data exist regarding excretion into breast milk; however, the potential for infant exposure warrants caution, and alternative antiemetics may be preferable.

Pediatric Considerations

• Palonosetron is approved for children aged 2 years and older for CINV; ondansetron is approved for a broader age range (neonates to adults). Dose adjustments are required based on weight and age.
• Children exhibit different pharmacokinetic profiles, including higher clearance rates for ondansetron; thus, dosing intervals may differ from adults.
• Monitoring for QTc prolongation is essential, as pediatric patients may be more susceptible to arrhythmias.

Geriatric Considerations

• Age‑related decline in hepatic and renal function may necessitate dose reduction for agents with significant organ clearance.
• Polypharmacy increases the risk of drug interactions, particularly with CYP3A4 inhibitors or inducers.
• Polypharmacy and comorbidities elevate the risk of QTc prolongation; ECG monitoring should be considered.

Renal and Hepatic Impairment

• Ondansetron and granisetron are primarily metabolised hepatically; mild to moderate hepatic impairment requires dose adjustment (e.g., 50 % reduction). Severe hepatic dysfunction may preclude use.
• Renal impairment has minimal impact on 5‑HT₃ antagonists, though dose adjustments are recommended in end‑stage renal disease.
• Aprepitant undergoes hepatic metabolism; in severe hepatic impairment (Child‑Pugh class C), use is contraindicated. In mild to moderate hepatic impairment, a 50 % dose reduction is advised.

Summary / Key Points

• 5‑HT₃ antagonists block serotonin‑mediated peripheral and central emetic pathways, while NK1 antagonists target substance P‑mediated central pathways.
• Palonosetron’s long half‑life and receptor internalisation confer extended protection against delayed CINV.
• Aprepitant’s CYP3A4 inhibition necessitates careful evaluation of concomitant medications to avoid toxicity.
• QTc prolongation is a significant safety concern, especially with ondansetron and granisetron; ECG monitoring is recommended in high‑risk populations.
• Special populations (pregnancy, lactation, pediatrics, geriatrics, renal/hepatic impairment) require individualized dosing and vigilant monitoring.
• Combination therapy with 5‑HT₃ and NK1 antagonists remains the most effective strategy for preventing both acute and delayed chemotherapy‑induced nausea and vomiting.

References

1. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
2. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
3. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
4. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
5. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
6. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
7. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
8. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.